| Optimal duration of extended adjuvant endocrine therapy for early breast cancer; results of the IDEAL trial (BOOG 2006-05) EJ Blok, JR Kroep, E Meershoek-Klein Kranenbarg, ... JNCI: Journal of the National Cancer Institute 110 (1), 40-48, 2018 | 180 | 2018 |
| Cytoplasmic overexpression of HER2: a key factor in colorectal cancer EJ Blok, PJK Kuppen, JEM van Leeuwen, CFM Sier Clinical Medicine Insights: Oncology 7, CMO. S10811, 2013 | 102 | 2013 |
| Cancer-immune interactions in ER-positive breast cancers: PI3K pathway alterations and tumor-infiltrating lymphocytes M Sobral-Leite, I Salomon, M Opdam, DT Kruger, KJ Beelen, ... Breast Cancer Research 21, 1-12, 2019 | 100 | 2019 |
| Systematic review of the clinical and economic value of gene expression profiles for invasive early breast cancer available in Europe EJ Blok, E Bastiaannet, WB Van den Hout, GJ Liefers, V Smit, JR Kroep, ... Cancer Treatment Reviews 62, 74-90, 2018 | 78 | 2018 |
| Adjuvant tamoxifen and exemestane in women with postmenopausal early breast cancer (TEAM): 10-year follow-up of a multicentre, open-label, randomised, phase 3 trial MGM Derks, EJ Blok, C Seynaeve, JWR Nortier, EMK Kranenbarg, ... The Lancet Oncology 18 (9), 1211-1220, 2017 | 66 | 2017 |
| Extended adjuvant endocrine therapy in hormone-receptor positive early breast cancer: current and future evidence EJ Blok, MGM Derks, JJM van der Hoeven, CJH van de Velde, JR Kroep Cancer treatment reviews 41 (3), 271-276, 2015 | 52 | 2015 |
| Estrogen receptor pathway activity score to predict clinical response or resistance to neoadjuvant endocrine therapy in primary breast cancer MA Inda, EJ Blok, PJK Kuppen, A Charehbili, ... Molecular cancer therapeutics 19 (2), 680-689, 2020 | 51 | 2020 |
| Abstract S1-04: Optimal duration of extended letrozole treatment after 5 years of adjuvant endocrine therapy; results of the randomized phase III IDEAL trial (BOOG 2006-05) EJ Blok, CJH Van de Velde, EM Meershoek-Klein Kranenbarg, H Putter, ... Cancer Research 77 (4_Supplement), S1-04-S1-04, 2017 | 43 | 2017 |
| Overestimation of late distant recurrences in high-risk patients with ER-positive breast cancer: validity and accuracy of the CTS5 risk score in the TEAM and IDEAL trials I Noordhoek, EJ Blok, E Meershoek-Klein Kranenbarg, H Putter, ... Journal of Clinical Oncology 38 (28), 3273-3281, 2020 | 27 | 2020 |
| Combined evaluation of the FAS cell surface death receptor and CD8+ tumor infiltrating lymphocytes as a prognostic biomarker in breast cancer EJ Blok, J van den Bulk, NG Dekker-Ensink, R Derr, C Kanters, ... Oncotarget 8 (9), 15610, 2017 | 27 | 2017 |
| Are pathological high-risk features in locally advanced rectal cancer a useful selection tool for adjuvant chemotherapy? M Swets, PJK Kuppen, EJ Blok, H Gelderblom, CJH van de Velde, ... European Journal of Cancer 89, 1-8, 2018 | 26 | 2018 |
| Strong CD8+ lymphocyte infiltration in combination with expression of HLA class I is associated with better tumor control in breast cancer patients treated with neoadjuvant … AF De Groot, EJ Blok, A Charehbili, CC Engels, V Smit, ... Breast cancer research and treatment 175, 605-615, 2019 | 19 | 2019 |
| 70-Gene Signature in Early-Stage Breast Cancer. EJ Blok, CJ van de Velde, VT Smit The New England journal of medicine 375 (22), 2199-2199, 2016 | 19 | 2016 |
| Exploration of tumour-infiltrating lymphocytes as a predictive biomarker for adjuvant endocrine therapy in early breast cancer EJ Blok, CC Engels, G Dekker-Ensink, E Meershoek-Klein Kranenbarg, ... Breast Cancer Research and Treatment 171, 65-74, 2018 | 17 | 2018 |
| Treatment decisions and the impact of adverse events before and during extended endocrine therapy in postmenopausal early breast cancer EJ Blok, JR Kroep, EMK Kranenbarg, M Duijm-de Carpentier, H Putter, ... European Journal of Cancer 95, 59-67, 2018 | 14 | 2018 |
| Relevant factors for the optimal duration of extended endocrine therapy in early breast cancer EJ Blok, JR Kroep, E Meershoek-Klein Kranenbarg, ... Breast Cancer Research and Treatment 168, 413-420, 2018 | 9 | 2018 |
| Integrin regulation by tissue factor promotes cancer stemness and metastatic dissemination in breast cancer B Ünlü, B Kocatürk, AMR Rondon, CS Lewis, N Swier, RFP van den Akker, ... Oncogene 41 (48), 5176-5185, 2022 | 5 | 2022 |
| Symptomatic rebound methaemoglobinaemia after treatment with dapsone BRP Jonkers, G Cobanoglu, EJ Blok, JJ Köbben, MW van der Helm, ... Neth J Med 78 (5), 277-281, 2020 | 4 | 2020 |
| Tumor-expressed factor VII is associated with survival and regulates tumor progression in breast cancer C Kroone, C Tieken, B Kocatürk, M Paauwe, EJ Blok, B Ünlü, ... Blood Advances 7 (11), 2388-2400, 2023 | 3 | 2023 |
| Abstract P2-09-08: Safety assessment of extended adjuvant endocrine therapy with letrozole; results of the randomized phase III IDEAL trial (BOOG 2006-05) EJ Blok, JR Kroep, EM Meershoek-Klein Kranenbarg, ... Cancer Research 77 (4_Supplement), P2-09-08-P2-09-08, 2017 | 2 | 2017 |
